Current Report Filing (8-k)
August 19 2022 - 8:02AM
Edgar (US Regulatory)
0001729427
false
0001729427
2022-08-18
2022-08-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 18, 2022
___________________________
CNS Pharmaceuticals, Inc.
(Exact name of registrant as specified in its
charter)
___________________________
Nevada |
001-39126 |
82-2318545 |
(State or other jurisdiction of
incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
2100 West Loop South, Suite 900
Houston,
Texas 77027
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (800) 946-9185
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
___________________________
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section
12(b) of the Act:
Title of each class |
Trading Symbols(s) |
Name of each exchange on which registered |
Common stock, par value $0.001 per share |
CNSP |
The NASDAQ Stock Market LLC |
Item 8.01.
Other Events.
As previously reported, on February 18, 2022,
CNS Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”)
of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for
the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital
Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).
In accordance with Nasdaq Listing Rule 5810(c)(3)(A)
(the “Compliance Period Rule”), the Company was provided an initial period of 180 calendar days to regain compliance with
the Bid Price Rule. The Company was eligible for a second 180 calendar day period to regain compliance if it met the continued listing
requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for
the minimum bid price requirement. In addition, to receive the second 180 calendar day extension, the Company was required to notify Nasdaq
of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split.
The Company requested an additional 180 days
in which to regain compliance, including by effecting a reverse stock split, if necessary, and, on August 18, 2022, the Company received
notice from Nasdaq informing the Company that it had been granted an additional 180-day period, or until February 13, 2023, to regain
compliance with the minimum bid price requirement. If, at any time before this date, the bid price for the Company’s common stock
closes at $1.00 or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that
it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing
Rule 5810(c)(3)(H).
If the Company does not regain compliance
with the Bid Price Rule by February 13, 2023, the Staff will provide written notification to the Company that its common stock will be
delisted. The Company would then be entitled to appeal the Staff’s determination to a NASDAQ Hearings Panel and request a hearing.
The Company intends to monitor the closing
bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which
could include effecting a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with
the Bid Price Rule.
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
CNS Pharmaceuticals, Inc. |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Chris Downs |
|
|
|
Chris Downs |
|
|
|
Chief Financial Officer |
|
Dated: August 19,
2022
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Jul 2023 to Jul 2024